Table 4.

Self-selection–corrected ORs showing association of cervical cancer and screening participation by morphology and stage

Age at invitationCases screened Y/NaControls screened Y/NaOR (95% CI)b
All cervical cancers25–69366/4943,469/1,8130.53 (0.46–0.62)
 25–39122/1731,028/8050.81 (0.63–1.05)
 40–54147/2101,527/6950.44 (0.35–0.56)
 55–6997/111914/3130.37 (0.27–0.52)
Squamous carcinoma25–69205/3272,134/1,2000.50 (0.41–0.61)
 25–3988/116703/5830.91 (0.67–1.24)
 40–5479/138931/4440.40 (0.29–0.54)
 55–6938/73500/1730.23 (0.14–0.37)
Adenocarcinoma25–69142/1351,129/5320.69 (0.53–0.91)
 25–3928/51270/1940.59 (0.36–0.98)
 40–5462/59511/2230.61 (0.41–0.91)
 55–6952/25339/1150.88 (0.50–1.54)
Stage IA25–6995/132850/5620.62 (0.46–0.84)
 25–3944/70403/3390.69 (0.45–1.07)
 40–5434/54346/1790.43 (0.27–0.70)
 55–6917/8101/441.12 (0.41–3.06)
Stage IB+25–69234/3092,269/1,0690.50 (0.41–0.61)
 25–3968/86546/3990.93 (0.65–1.32)
 40–54102/1321,026/4450.47 (0.35–0.63)
 55–6964/91697/2250.27 (0.18–0.40)
Stage IB+ squamous carcinoma25–69114/1871,275/6340.44 (0.35–0.56)
 25–3944/48329/2551.04 (0.68–1.58)
 40–5448/81573/2590.39 (0.27–0.56)
 55–6922/58373/1200.19 (0.11–0.32)
  • aNumber of cases and controls with invitation and exposed to screening yes/no.

  • bEstimated using conditional logistic regression and corrected for self-selection.